Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 17/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | BMX | P51813 | 1/20 | 0.36 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15613509 | 0.87 | BTK (0.35) | BTK | |
| SCHEMBL15613776 | 0.85 | BTK (0.37) | BTKEGFRSRCBMXNR4A3 | |
| SCHEMBL15613543 | 0.84 | SRC (0.48) | BTKEGFRSRC | |
| SCHEMBL15613663 | 0.84 | BTK (0.44) | BTKEGFRSRCBMXNR4A3 | |
| SCHEMBL15613782 | 0.80 | BTK (0.37) | BTK | |
| SCHEMBL15613605 | 0.80 | BTK (0.36) | BTK | |
| SCHEMBL15613651 | 0.78 | BTK (0.35) | BTKEGFRSRC | |
| SCHEMBL15613747 | 0.78 | BTK (0.48) | BTK | |
| SCHEMBL19490428 | 0.76 | BTK (0.38) | BTK | |
| SCHEMBL15613549 | 0.75 | BTK (0.51) | BTKEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796716-B2 | Selective inhibitors of Tec and Src protein kinase families | PHARMASCIENCE, INC. (CA) | 2017-10-24 | — | — | US | disclosed |
| US-20150191473-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE, INC. (CA) | 2015-07-09 | — | — | US | disclosed |
| WO-2013177668-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE, INC. (CA) | 2013-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191473-A1 | PROTEIN KINASE INHIBITORS | TEC, SRC, LCK | BTK 10/4885EGFR 521/4885SRC 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.